Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Amgen Infergen may be marketed as hepatitis C relapse treatment, firm tells analysts.

Executive Summary

AMGEN INFERGEN MARKETING MAY TARGET HEPATITIS C RELAPSERS, statements by Chief Financial Officer Robert Attiyeh at a June 4 Paine Webber analysts meeting in New York City indicated. Attiyeh said that pivotal trials with the drug yielded a "durable response in 58% of the relapsers" who have undergone existing interferon therapy. Infergen (consensus interferon) was deemed "approvable" by FDA in April. "We're simply negotiating the final terms and conditions of the package insert. We expect approval to go to the market later this year," Attiyeh said. Yamanouchi licensed rights to market Infergen in all markets except North America.
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS030310

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel